MRNA-1345 is under clinical development by Moderna and currently in Phase III for Respiratory Syncytial Virus (RSV) Infections. According to GlobalData, Phase III drugs for Respiratory Syncytial Virus (RSV) Infections have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how MRNA-1345’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
mRNA-1345 is under development for the prevention of respiratory syncytial virus (RSV) infection in young children and adults. It comprises of lipid nanoparticles encapsulated mRNAs encoding for a prefusion F glycoprotein. The therapeutic is developed based on lipid nanoparticles (LNP) technology and mRNA expression platform. It is administered through parenteral and intramuscular route.
Moderna operates as a developer of messenger RNA therapeutics. The company develops and discovers drugs that produce proteins or antibodies inside patient cells. Its pipeline includes various drug modalities such as prophylactic vaccines, therapeutic vaccines, intratumoral immuno-oncology, localized therapeutics, and liver intracellular. Moderna through its mRNA therapeutics platform develops and produces human proteins, antibodies, and novel proteins, which help in preventing, treating, and curing diseases. It also develops therapeutics in the areas of infectious disease, rare liver disease, immuno-oncology, and cardiovascular disease. Moderna Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of MRNA-1345’s drug-specific PTSR and LoA scores, buy the report here.